Zelpultide alfa
Peptide
Zelpultide alfa is one of 29 small molecule programs targeting Bronchopulmonary Dysplasia. It is currently in development.
1
Indications
1
Total Trials
1
Active Trials
28
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
56 competitors in Bronchopulmonary Dysplasia
#DrugCompanyPhaseTrials
1Biaxin
AbbVieApproved
Pulmicort
SSalix
Approved
Qvar
SSchering-Plough
Approved
Zithromax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Tobrex
VViatris Specialty LLC
Approved
Medrol
PfizerPhase 3
CUROSURF
Chiesi Farmaceutici S.p.A.Approved
Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Decadron
AAspen Global Incorporated
Phase 3
Vivarin
HHikma Pharmaceuticals LLC
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Zelpultide alfa. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Peptide[2]
- Company
- AAirway Therapeutics, Inc.